Alternatives to Immitra Bio
Immitra Bio is a Biotechnology tool: scalable, one-time curative in-vivo gene editing therapies. Here are the 60 closest alternatives, compared on pricing, features and what real users say.
The 20 closest Biotechnology companies to Immitra Bio
- Website
CRISPR Therapeutics64BiotechnologyZug, Switzerland$547.0MBiotechnology company developing transformative gene-based medicines using CRISPR/Cas9 gene editing technology.
- Website
Editas Medicine42BiotechCambridge, United States$210.0MA clinical-stage biotechnology company developing transformative genome editing medicines for serious diseases.
- Website
Intellia Therapeutics40BiotechCambridge, United States$310.0MA clinical-stage genome editing company developing novel therapies using CRISPR/Cas9 technology for severe diseases.
- Website
Moderna77BiotechnologyCambridge, United States$4.5BModerna is a biotechnology company pioneering mRNA medicine, best known for its COVID-19 vaccine and a broad pipeline of mRNA-based therapeutics.
- Website
Mammoth Biosciences63BiotechnologyBrisbane, United States$460.0MBiotechnology company leveraging ultracompact CRISPR systems for gene editing therapies and diagnostics.
- Website
Epicrispr Biotechnologies62BiotechnologySouth San Francisco, United States$90.0MEpicrispr Biotechnologies is a biotechnology company developing novel epigenetic therapies, with a lead program targeting Facioscapulohumeral Muscular Dystrophy (FSHD).
- Website
Network Bio60BiotechnologyPalo Alto, United States$100.0MLeveraging AI and a massive patient tissue dataset to accelerate drug discovery and advance precision medicine.
- Website
Infinimmune60BiotechnologyAlameda, United States$75.0MDeveloping human-derived antibodies for inflammatory diseases and cancer using AI and proprietary platforms.
- Website
LifeMine Therapeutics Inc.60BiotechnologyWatertown, United States$543.0MClinical-stage biopharmaceutical company leveraging a proprietary platform to discover and develop novel precision medicines from fungi.
- Website
CellCentric60BiotechnologyCambridge, United Kingdom$375.0MA clinical-stage biotechnology company developing inobrodib as a first-in-class, oral p300/CBP inhibitor for the treatment of multiple myeloma.
- Website
Freenome59BiotechnologySouth San Francisco, USA$570.0MFreenome is a biotechnology company developing a multi-cancer early detection blood test using machine learning and biology.
- Website
Mironid59BiotechnologyGlasgow, United Kingdom$46.0MBiopharmaceutical company developing novel small-molecule therapeutics for rare kidney diseases, particularly Autosomal Dominant Polycystic Kidney Disease (ADPKD).
- Website
Spark Therapeutics58BiotechnologyPhiladelphia, United States$82.8MA biotechnology company developing gene therapy treatments for rare, debilitating genetic diseases.
- Website
Rocket Pharmaceuticals57BiotechnologyCranbury, USA$382.9MA biotechnology company developing genetic therapies for rare disorders.
- Website
KaliVir Immunotherapeutics, Inc.57BiotechnologyPittsburgh, United States$14.0MClinical-stage biotechnology company developing multi-mechanistic oncolytic immunotherapy programs for cancer treatment.
- EAEarendil Labs56BiotechnologyBeijing, China$787.0M
Earendil Labs is an AI biotechnology company focused on leveraging artificial intelligence for drug discovery and development of next-generation biologics.
- Website SPSpliceBio54BiotechnologyCambridge, United States$100.0M
Biotechnology company developing next-generation gene therapies using a proprietary protein splicing platform.
- Website
Latus Bio54BiotechnologyBoston, USA$151.0MEngineering scalable gene therapies for broader patient populations.
- Website KHKhartis Therapeutics, Inc.53BiotechnologySan Diego, United States$50.0M
Developing oral small molecule medicines for immunological and chronic diseases.
- Website
Ray Therapeutics53BiotechnologyBerkeley, USA$243.0MPioneering vision restoration therapies for severe retinal degenerations.
Showing the 20 closest matches. See the rest on the Immitra Bio profile.